Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Times cited: 82
Outcome of deferred initial therapy in mantle-cell lymphoma.
Journal of Clinical Oncology.
Times cited: 185
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Times cited: 142